Skip to content
Open access

Heparin-calibrated anti-factor Xa activity as a surrogate marker for direct oral anticoagulant levels in acute stroke care: a large observational single-center study

Aug 2026 · Neurological Research and Practice · Vol 8 · 0 citations · 20 references
Medicine

TL;DR

Defined anti-Xa cut-offs are highly specific and sensitive and enable rapid and standardized assessment of anticoagulant activity in this cohort and Heparin-calibrated anti-Xa activity is a reliable surrogate marker for clinically relevant DOAC levels.

Abstract

Direct oral anticoagulants (DOAC) complicate therapeutic decision-making, as rapid assessment of anticoagulant activity is critical in emergency patients, particularly in acute ischemic stroke (AIS). The administration of systemic thrombolysis (IVT) in anti-coagulated patients requires careful risk–benefit evaluation, given the potential for hemorrhagic complications. Substance-specific DOAC plasma level measurements are often unavailable outside tertiary centers. This study evaluated whether widely available heparin-calibrated anti-factor Xa (anti-Xa) activity can reliably estimate clinically relevant DOAC levels and support urgent clinical decision-making. This retrospective single-center study (2015–2023) analyzed 969 patients treated with apixaban, rivaroxaban, or edoxaban. All patients had parallel measurements of anti-Xa activity and specific DOAC levels. Correlations were assessed using Spearman’s coefficient. Receiver operating characteristic (ROC) analyses were performed to derive anti-Xa cut-off values corresponding to DOAC concentrations of 30, 50, and 100 ng/mL. Anti-Xa activity strongly correlated with DOAC plasma levels for all substances (Spearman’s ρ ≈ 0.95–0.96). ROC analyses demonstrated excellent diagnostic accuracy, with areas under the curve ≥ 0.97 for all evaluated thresholds. Similar anti-Xa cut-offs were observed for apixaban and rivaroxaban, whereas these were lower for edoxaban. For all DOACs combined, anti-Xa cut-offs of approximately 0.36U/mL, 0.56U/mL, and 1.19U/mL corresponded to DOAC levels of 30, 50, and 100ng/mL, respectively, with high sensitivity and specificity. Heparin-calibrated anti-Xa activity is a reliable surrogate marker for clinically relevant DOAC levels. Defined anti-Xa cut-offs are highly specific and sensitive and enable rapid and standardized assessment of anticoagulant activity in this cohort.

Read PDF

Similar papers

Open access Aug 2026

Real-World Assessment of Direct Oral Factor Xa Inhibitors: Dosing Appropriateness, Drug Exposure, and Inter-Platform Comparability of Chromogenic Anti-Xa Assays

Background/Objectives: Direct oral factor Xa inhibitors (DOACs) show substantial interindividual exposure variability in real-world practice, yet interpretation of plasma drug concentrations remains challenging because routine monitoring is not standardized. This study evaluated dosing appropriateness, plasma drug expo...

Yoonjung Kim, Sojin Lee, Yongjung Park et al. · 0 citations
Aug 2026

Comparative Effectiveness and Outcomes of Direct Oral Anticoagulants vs. Vitamin K Antagonists (VKA) in Atrial Arrhythmias Patients with Isolated Lupus Anticoagulant Without Antiphospholipid Syndrome: A Real-World Cohort Analysis.

BACKGROUND Direct oral anticoagulants (DOACs) are preferred over VKA for stroke prevention in atrial fibrillation/flutter (AF), but concerns exist regarding their use in antiphospholipid syndrome (APS). The safety and effectiveness of DOACs in AF patients with isolated lupus anticoagulant (LA) who do not meet APS crite...

Omar Obeidat, Laith Alhuneafat, Mohamed F. Ismail et al. · 0 citations
Open access Aug 2026

Dose and Time Dependent Elevations of Initial Unfractionated Heparin Anti-Xa Levels Associated With Low Molecular Weight Heparin Administration.

Background Intravenous unfractionated heparin (UFH) is routinely utilized for anticoagulation in acute care patients. Appropriate laboratory monitoring is an essential component of UFH therapy, including minimizing the effect of variables that interfere with the monitoring assays. While alterations in anti-factor Xa (a...

Ananth M. Anthes, Sarah Providence, Xinhua Zhao · 0 citations
Open access Sep 2026

Is the International Normalized Ratio (INR) Enough? Reevaluating INR-Based Decision-Making for Four-Factor Prothrombin Complex Concentrate in Geriatric Warfarin-Associated Intracranial Hemorrhage: A Multicenter Cohort Study

Background/Objectives: Warfarin-associated intracranial hemorrhage (WA-ICH) remains one of the most devastating anticoagulant-related emergencies, particularly among older adults, with substantial morbidity and mortality. Although current guidelines recommend that reversal strategies should be guided primarily by bleed...

Y. Doğan, Akkan Avci, Ramazan Guven et al. · 0 citations
Review Open access Aug 2026

The role of anti-Factor-Xa monitoring in the dosing and administration of low molecular weight heparins in pregnancy: a systematic review and meta-analysis.

BACKGROUND Our aim was to determine the risk of thromboembolic complications (TECs) and major bleeding with weight-based, fixed- and anti-Xa-monitored dosing of low molecular weight heparins (LMWH) during pregnancy. METHODS We conducted a systematic review wherein we searched seven databases for articles published be...

R. Ashraf, D. Mohamed, Shahab Sayfi et al. · 0 citations
Review Open access Sep 2026

Comparing outcomes using low-dose apixaban and anti-Xa monitoring and vitamin K antagonists in patients with renal replacement therapy.

BACKGROUND Guidelines recommend oral anticoagulation for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism. Outside the United States, apixaban is unlicensed for use in patients with end-stage renal disease (ESRD) receiving renal replacement therapy (RRT). AIM To compare thro...

J. Bartoli-Abdou, Alexander T. Cohen, Lucy Vernon et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.